Poolbeg Pharma Share Discussion Threads

[pogue] 13/10/2024 08:54

Peterrr3
I go to plenty events to window shop, going to an event does not mean there is a fundraise going to happen, I suggest you are taking one presentation out of context and extrapolating to the moon.
I don’t see where they need the funds to be honest. They started out 3 years ago with around £20 million and now have around £10 million and are trailing POLB001 with 2 pharma companies’ drugs which suggests they are in advanced talks as if they goto human trial, they have done the In Vivo animal trial, there would have to be a contract signed setting out the partnership/selling deal should the result be positive as is normal in these situations in industry. No pharma company would want to increase the value of a 3rd party drug by proving it successful without having a price fixed beforehand. Why fundraise when you are that close to a massive monetisation of your lead asset?
Why are they trying to find an orphan drug to sell? Well to make money perhaps? POLB have a pipeline of drugs they develop and sell/partner. Pentoxifylline has past phase II so they don’t need to put it through a trial. I don’t know what the deal will be with the owner but I cannot see POLB buying it unless they have a buyer. I suggest the most likely is a partnership where POLB help sell the drug and share in the profits. This is a capital light company they don’t spend money unless they have to bringing on drugs, have you seen the very small quantities of cash they have spent on the existing drugs in the pipeline? The fact they have spent only £10 million or so over 3 years is a clue.
As I said I have listened to the Liam Trimble go on about POLB’s encapsulation tech being used in a trail later this year all 43 seconds off it and did not get excited about at the time as an oral encapsulation trial was being planned from the beginning of this year and was initially down to happen July/August so not seeing what the issue is, nothing new in it. The cost will be small and is being tested for use with another company’s drug they will contribute in some way same as those pharmas running the POLB001 trials did. The trial is very simple for encapsulation. Volunteer comes into medical establishment, pops a pill come backs next day to get a blood test to see if the drug has dispersed in their system, you really think they need a fundraise for this and it hasn’t been planned for? It is not the drug that’s being tested its oral encapsulation so not dangerous or expensive do you really think a sudden fundraise is needed for that as it has been planned for for a long time?
As I said POLB does not have an obesity drug it’s the encapsulation that is being trailed. Should the trial work then there is a vast market out there for oral encapsulation way outside obesity drugs. Really cant see what you are going on about there.
So to summarise why do you think they need a fundraise when they are getting close to a deal on POLB001? Oral encapsulation has been planned for trial for a long time and is not expensive to do. Pentoxifylline does not belong to POLB, they have an option on it and is past phase II so what cash do they need to spend as the option will more than likely be on a deal to sell in partnership with current owner and they dont need to conclude the deal if they see no buyers.

[spuddymadrid] 13/10/2024 08:21

Hehe Malcolm like Baldrick you are throwing tantrums when the company prospects look good. Another unusual shareholder who wants the share price to drop. Could also be mistaken for believing you are short or shorting the share. Good look with your strategy my friend.

[malcolmz1] 12/10/2024 23:02

You are nuts to believe what CF says. You should have learned your lesson with HVO. 50m China deals, DIM, Google, fit it, amazon....... Ffs

[malcolmz1] 12/10/2024 23:01

Do you believe what Cathal says? Really?

[spuddymadrid] 12/10/2024 20:16

Funny Baldrick from your repetitive comments one might be mistaken in believing you want the share price to drop. Surely not if you are a shareholder hehe !!

[baldrick1] 12/10/2024 17:55

It's almost fake news that saved the share price rot .What come Monday???;)))

[peterrr3] 12/10/2024 16:20

Pogue why go to an event whose sole purpose is to obtain a placement? Why schedule in an obesity phase one in late 2024 and spend the whole year trying to find an orphan drug to sell? Because POLB is the deal? Possibly but given the above I don't think so.The early discussion the CEO said was with thought leaders, which ain't pharma. Their job is to influence pharma and the CEO said a few times it was early days.Are we really watching the same presentations? Did you watch the ones from the principal scientist like I suggested? Are you suggesting what he said was the focus isn't?

[pogue] 12/10/2024 11:37

Peter
Why do a raise when you are in no urgent need of cash and are in discussions on partnering/selling POLB001? Maybe if this was late next year and no sign of income. Plenty of cash just now and the share price is too low to do consider doing one prematurely.

[1gw] 11/10/2024 16:39

I think a successful reverse, with a fundraise, would also get them out of the hole in terms of the early statements they made about not having to raise money again given their asset-light and early monetisation approach. They can spin a reverse with fundraise as a way of letting in US investors.

But they've been talking about the reverse for a long time so I will believe it when I see the RNS confirming it's happening.

[peterrr3] 11/10/2024 15:34

The CEO didn't go to Wainwright for a cup of tea and a chinwag, it is a placement specialist. I am guessing no interest in investment while sitting on AIM.

[chica1] 11/10/2024 14:51

How is that legal to make a comment like that without informing the market first in an RNS?

That is market sensitive information!

[1gw] 11/10/2024 14:20

Incidentally, in the text of that 15th Feb announcement and in the 2023 annual report it states that the principal vesting condition is a 17.9p share price, whereas in the MAR notices for individual employees at the bottom of the announcement it states 16.5p.

I wonder if that might be an issue one day? (Chance would be a fine thing)

[1gw] 11/10/2024 14:03

That's an interesting theory on the EIP options peterrr3. But if Poolbeg shareholders have control of the merged company after a reverse, has there been a change of control of Poolbeg, if that's what you're referring to?

"The EIP Options are also subject to acceleration in certain scenarios including a change of control of the Company."

[peterrr3] 11/10/2024 13:31

Pogue I have paid reasonable attention to the presentations, CF earlier said a NASDAQ listing was too early as it cost a lot and they needed a source of income first, hence the hunt for market ready orphan drugs. Did you have a look at the interview with the lead scientist last week?The trial I thought would be the GLP 1R. They can afford to start this before the end of the year and it is flagged and you can spin it any which way but on their website they chose obesity. They need cash they don't have for any POLB phase 2, that needs a cap raise/ placement.I think the overall motivation is the grant shares though.

[pogue] 11/10/2024 13:08

Peter
Trying to multitask so just reread your post again. So many errors its amazing.
You do know they are not trialing an obesity drug dont you?
Again watch the presentations before saying anything you are very poorly researched and are just shooting from the lip in a troll like manner.

[sikhthetech] 11/10/2024 13:03

question is how much will they want to raise as part of US listing.
If so, will they go for a deep discounted placing?

US listings, especially dual listings, don't always work. Look at Trmr, now Nexn. Their IPO for a dual listing in 2021. I warned of the challenges. 1gw and his mates were ramping trmr at 800p+++
The company went for the IPO, raised over $100m in a deeply discounted placing, even though the company was supposedly doing well, broker's forecasts unrealistic etc !!!!


The shares crashed soon after with profit warnings etc. Currently after 4 years, Nexn is trading around 300p, around 1/3 of the price.

After the shares crashed, the usual 'obvious' comments started appearing.
'How we laughed' at Sikh etc




Ask 1gw, he and his mates were overplaying the potential and underplaying the risks.

As I say best to trade and question and check everything posted by 1gw and his mates....
He has a long history of virtually all his shares crashing. Look at Byot, Rthm, Trmr, Blnx, Inse, NTQ, stu, Nano, GBO etc etc

Don't take my word for it, check the shares yourselves.

[pogue] 11/10/2024 13:00

peterrr
the NASDAQ move has been flagged in most presentations this year by JS as happening before year end. It was a casual remark in an intervierw last night with CF and about his life and had very little to do with POLB. Think you are projecting too much. Watch the video. Watch some presentations even.
Edit
he loaded up here, and many others did, not because of NASDAQ but quite simply the cancer drug pharmas need POLB001, again some watching presentations would help your undertanding.

[peterrr3] 11/10/2024 12:39

This is what I reckon, drawing a bit of a long bow, so cut me some slack.Has to be NASDAQ as it is a trigger event for the release of the management grant shares, otherwise they needed 18p for 2 weeks and would have run out of money first.CF would not put his balls on the line with 2 months to go in the year with such a direct statement. Maybe why he cashed out of HVIVO in preparation.CTI will probably run the obesity trial as it looks like they are recruiting for one and keep popping up in the background. Alternatively they are orphan drug trial specialists.

[lawson27] 11/10/2024 11:21

Joined you for the recovery here, GLA

[pogue] 11/10/2024 09:19

1gw
it has been the plan for a long time. JS has said it would happen by year end a few times in presentations.
It will off course be reversing into another company over there so wont need to meet the NASDAQ criterion for listing so can happen quickly.

[1gw] 11/10/2024 08:24

Start listening around 11:22 if you don't want to wade through the whole thing.

"We've guided the market Poolbeg will go on Nasdaq later this year so that will really get some life into it." (as I hear it)

Pinch of salt required, I would suggest, but you never know.

[spuddymadrid] 11/10/2024 08:09

Nasdaq listing to take place this year as per this interview released yesterday

hxxps://youtu.be/dMRAbhrJdN0?si=dnpSQ9uw1WeWhPN8